IP Library Granted Patent US 9,765,043
Granted Patent B2
US 9,765,043 · App. 14/466,852 · Granted Sep 19, 2017

Salts of potassium ATP channel openers and uses thereof

Inventors: Neil M. Cowen (Carlsbad, CA); Richard C. Pasternak (New York, NY)
Assignee: Essentialls, Inc.
C07D285/24A61K31/14A61K31/192A61K31/202A61K31/44A61K31/549A61K31/655A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,765,043
App. No.
14/466,852
Granted
Sep 19, 2017
Kind
B2
Abstract

Provided are immediate or prolonged administration of certain salts of K ATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Claims (7)

1. A method for treating a subject with acute pancreatitis and elevated triglycerides, the method comprising intravenously administering a dose of 100-400 mg per day of a K ATP channel opener;

wherein said K ATP channel opener is diazoxide or a salt thereof.

2. The method of claim 1 , wherein said K ATP channel opener comprises a salt of diazoxide.

3. The method of claim 1 , wherein said K ATP channel opener comprises diazoxide choline.

4. The method of claim 1 , wherein the K ATP channel opener comprises diazoxide.

5. The method of claim 1 , further comprising co-administration of nicorandil.

6. The method of claim 1 , further comprising additional administration of diazoxide or a salt thereof, after completion of the dose of 100-400 mg per day, at between about 0.02 to 0.2 mg/kg/hr, along with administration of insulin on a recurring basis at a level and rate sufficient to maintain fasting glucose between about 70 mg/dL and 125 mg/dL and peak post prandial glucose less than 200 mg/dL.

Assignments (6)
SECURITY INTEREST Recorded Jun 26, 2026
From: SOLENO THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075106/0487 →
RELEASE OF SECURITY INTEREST (REEL 070494, FRAME 0042) Recorded May 19, 2026
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: SOLENO THERAPEUTICS, INC.; ESSENTIALIS, INC.
Reel/Frame 075601/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2025
From: ESSENTIALIS, INC.
To: SOLENO THERAPEUTICS, INC.
Reel/Frame 073832/0312 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 12, 2025
From: SOLENO THERAPEUTICS, INC.; ESSENTIALIS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 070494/0042 →
SECURITY INTEREST Recorded Dec 17, 2024
From: SOLENO THERAPEUTICS, INC.; ESSENTIALIS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 069613/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2014
From: COWEN, NEIL M.; PASTERNAK, RICHARD C.
To: ESSENTIALIS, INC.
Reel/Frame 033692/0917 →
Continuity (3)
Continuation PCTUS2013027676 · Feb 25, 2013
Provisional Application 61603923 · Feb 27, 2012
Related Publication 20140364425A1 · Dec 11, 2014